On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient population, reinforcing the company’s forecast that the drug could generate more than $5 billion in peak annual sales. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027. AstraZeneca believes it could reach a broader group of COPD patients than existing biologics that only target those with high eosinophil counts.
Bull Case
Tozorakimab could address a major broader COPD population than competing biologics. The two late-stage trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations by 29% to 34%, with benefits across patients regardless of eosinophil levels, smoking status, or disease severity. The broad efficacy could give AstraZeneca PLC (NYSE:AZN) access to patients who fall outside the populations currently targeted by competing biologics such as Regeneron and Sanofi’s Dupixent and GSK’s Nucala. The highest-eosinophil subgroup saw a particularly strong 43% reduction in exacerbations, further supporting the drug’s potential clinical differentiation.
The results solidify AstraZeneca’s respiratory growth pipeline. Tozorakimab gives the business another potential blockbuster as AstraZeneca targets $80 billion in annual revenue by 2030. CEO Pascal Soriot said the drug’s commercial potential could exceed the company’s previously raised $5 billion peak-sales estimate. It shows the size of the COPD market and the drug’s potential use across the patient population. The successful trials give investors a potentially real future revenue contributor beyond AstraZeneca’s existing medicines.
AstraZeneca can add to an already-growing respiratory and oncology franchise. The company’s oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year. Hence, Tozorakimab would enter an established commercial platform with significant experience selling specialty medicines to respiratory patients. Strong existing growth could give AstraZeneca time to develop the drug’s market opportunity while other products generate revenue and cash flow.
Bear Case
Tozorakimab still faces a significant regulatory hurdle before AstraZeneca PLC (NYSE:AZN) can monetize the opportunity. The FDA has not yet approved the drug, and AstraZeneca expects a decision in the first quarter of 2027. Priority review can shorten the regulatory process, but it does not guarantee approval. Any regulatory concerns or delays could push back the launch and postpone the revenue contribution that investors expect from the potential blockbuster.
The drug still needs to prove its commercial advantage against established COPD treatments. Although the late-stage results showed overall efficacy, the trials did not directly compare tozorakimab with established biologics such as Dupixent or Nucala. So AstraZeneca still needs to show how physicians should position the drug within the treatment landscape, particularly among higher-eosinophil patients who already have established biologic options. Without clear superiority or differentiation, the firm could face pricing pressure and slower adoption despite the encouraging trial results.
Tozorakimab cannot immediately offset pressure from AstraZeneca’s established drugs. Even if the FDA approves the treatment in 2027, the drug will need years to build a substantial commercial base and approach its projected $5 billion-plus peak sales. Meanwhile, AstraZeneca faces patent-expiry pressure on established products including Farxiga and Brilinta. This means investors still depend on other products and pipeline launches to sustain revenue growth in the near term. Tozorakimab could become a major long-term growth driver, but its eventual success will not eliminate AstraZeneca’s near-term need to replace declining revenue from older medicines.
Hedge Fund Sentiment
AstraZeneca PLC (NYSE:AZN)’s hedge fund following was little changed at 55 funds in the second quarter versus 56 in the first, with position value roughly flat at $5.53 billion, according to Insider Monkey’s database. Regeneron, whose Dupixent competes directly in the COPD biologic market that tozorakimab is targeting, saw hedge fund interest decline over the same period, with holders falling to 63 from 72 and position value dropping to $2.77 billion from $3.24 billion.
Conclusion
AstraZeneca achieved strong trial results for its drug tozorakimab, giving the company a major opportunity to treat COPD across a broad patient group. Experts project the drug’s peak annual sales will top $5 billion, which will help drive management’s goal of reaching $80 billion in total company revenue by 2030. However, the treatment still needs FDA approval and must prove its commercial advantage against established biologics. At the same time, AstraZeneca faces patent expiration pressure on its older medicines. The company’s overall success in converting trial data into a successful launch and sustained market sales will ultimately decide the drug’s true value to its long-term growth strategy.
READ NEXT: Cook Hands Ternus Apple (AAPL) that Still has to Prove itself on AI and Meta’s $18 Billion Settlement Could Be the Green Light for a New AI Push.
Hedge Fund Resource Center